Literature DB >> 8789614

Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain.

I A Paterson1, B A Davis, D A Durden, A V Juorio, P H Yu, G Ivy, W Milgram, A Mendonca, P Wu, A A Boulton.   

Abstract

The present study has examined whether MAO-B has a role in DA metabolism in the primate CNS in situ. Eleven macaques (macaca facicularis) were used in this study to examine the effects of (-)-deprenyl (1 mg/kg, i.v., 2 and 24 hours). (-)-Deprenyl administration completely and selectively blocked MAO-B activity and blocked DA metabolism in the caudate nucleus and frontal cortex. DA metabolism in the substantia nigra was not affected by MAO-B inhibition. Changes in DA metabolism were accompanied by changes in 5-hydroxytryptamine (5HT) turnover: 5-hydroxyindole acetic acid (5HIAA) levels increased in the caudate and decreased in the frontal cortex. Levels of 2-phenylethylamine (PE), a putative modulator of dopaminergic transmission, were increased by MAO-B inhibition in all three brain regions examined. It is concluded that in some regions of the primate brain, in contrast to the rat, MAO-B has an important role in DA metabolism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8789614     DOI: 10.1007/bf00970600

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  41 in total

1.  Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid.

Authors:  L J Major; D L Murphy; S Lipper; E Gordon
Journal:  J Neurochem       Date:  1979-01       Impact factor: 5.372

2.  Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

Authors:  P Riederer; M B Youdim
Journal:  J Neurochem       Date:  1986-05       Impact factor: 5.372

Review 3.  Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

Authors:  O Hornykiewicz
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

4.  Turnover kinetics of dopamine and norepinephrine in the forebrain after kindling in rats.

Authors:  D M Wilkison; L M Halpern
Journal:  Neuropharmacology       Date:  1979-02       Impact factor: 5.250

5.  The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.

Authors:  S R Philips; A A Boulton
Journal:  J Neurochem       Date:  1979-07       Impact factor: 5.372

6.  Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem.

Authors:  C Konradi; E Svoma; K Jellinger; P Riederer; R Denney; J Thibault
Journal:  Neuroscience       Date:  1988-09       Impact factor: 3.590

7.  Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.

Authors:  P H Yu; B A Davis; A A Boulton
Journal:  J Med Chem       Date:  1992-10-02       Impact factor: 7.446

8.  Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.

Authors:  A J Azzaro; J King; J Kotzuk; D D Schoepp; J Frost; S Schochet
Journal:  J Neurochem       Date:  1985-09       Impact factor: 5.372

9.  The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.

Authors:  C J Fowler; M S Benedetti
Journal:  J Neurochem       Date:  1983-06       Impact factor: 5.372

10.  The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine.

Authors:  M D Berry; E Scarr; M Y Zhu; I A Paterson; A V Juorio
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

View more
  2 in total

1.  Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.

Authors:  M K Lakshmana; B S Rao; N K Dhingra; R Ravikumar; S Sudha; B L Meti; T R Raju
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

2.  Modification of L-DOPA pharmacological activity by MAO inhibitors.

Authors:  J P M Finberg; O Sader-Mazbar
Journal:  J Neural Transm (Vienna)       Date:  2007-04-10       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.